Open Access
| Issue |
BIO Web Conf.
Volume 214, 2026
The 2025 International Conference on Biomedical, Bioinformatics and Statistics (ICBBS 2025)
|
|
|---|---|---|
| Article Number | 01003 | |
| Number of page(s) | 5 | |
| Section | Biomedical, Bioinformatics and Statistics | |
| DOI | https://doi.org/10.1051/bioconf/202621401003 | |
| Published online | 02 February 2026 | |
- J.L. Neul, et al., Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68, 944–950 (2010). https://doi.org/10.1002/ana.22124 [Google Scholar]
- M.J. Lyst, A. Bird, Rett syndrome: a complex disorder with simple roots. Nat. Rev. Neurosci. 16, 261–275 (2015). https://doi.org/10.1038/nrn3916 [Google Scholar]
- X. Nan, et al., Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386–389 (1998). https://doi.org/10.1038/30764 [Google Scholar]
- M. Chahrour, et al., MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224–1229 (2008). https://doi.org/10.1126/science.1153252 [CrossRef] [PubMed] [Google Scholar]
- J.L. Neul, et al., Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat. Med. 29, 1689–1697 (2023). https://doi.org/10.1038/s41591-023-02498-5 [Google Scholar]
- U.S. FDA, Daybue (trofinetide) Prescribing Information / Clinical Review (2023). https://www.accessdata.fda.gov/drugsatfda_docs/n da/2023/214745Orig1s000TOC.cfm [Google Scholar]
- Y. Wen, et al., MECP2 mutation spectrum and its clinical characteristics in a large Chinese cohort. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 37 (6) (2020). https://doi.org/10.3760/cma.j.cn511374-20191022-00591 [Google Scholar]
- M.C.N. Marchetto, et al., A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527–539 (2010). https://doi.org/10.1016/j.cell.2010.10.016 [Google Scholar]
- P.V. Belichenko, et al., Widespread changes in dendritic and synaptic structure in a mouse model of Rett syndrome. Hum. Mol. Genet. 18, 143–150 (2009). https://doi.org/10.1093/hmg/ddn330 [Google Scholar]
- R.E. Amir, et al., Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185–188 (1999). https://doi.org/10.1038/13810 [Google Scholar]
- L. Zhang, et al., MeCP2 in the nucleus accumbens contributes to neural and behavioral homeostasis. Cell Res. 26, 959–962 (2016). https://doi.org/10.1038/cr.2016.83 [Google Scholar]
- D.M. Katz, et al., Rett syndrome: crossing the threshold to clinical translation. Trends Neurosci. 39, 100–113 (2016). https://doi.org/10.1016/j.tins.2015.12.008 [Google Scholar]
- K.M. Keeling, et al., Therapeutics based on stop codon readthrough. Annu. Rev. Genomics Hum. Genet. 15, 371–394 (2014). https://doi.org/10.1146/annurev-genom-091212-153527 [Google Scholar]
- O.S. Khwaja, et al., Safety, pharmacokinetics, and preliminary efficacy of mecasermin (recombinant human IGF-1) for Rett syndrome. Neurology 82, 136–144 (2014). https://doi.org/10.1212/WNL.0000000000000030 [Google Scholar]
- H. Leonard, S. Cobb, J. Downs, Clinical and biological progress over 50 years in Rett syndrome. Nat. Rev. Neurol. 13, 37–51 (2017). https://doi.org/10.1038/nrneurol.2016.186 [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.